论文部分内容阅读
目的:回顾细胞集落刺激因子进展,借以评价其疗效及安全性。方法:采用近年来国内、外文献进行综述。结果与结论:于2 0世纪90年代上市的细胞集落刺激因子,作为生物工程药品中多肽类的代表,进展十分迅猛,临床应用也同步增多,近期国内、外专业文献的有关报道亦浩如烟海。大量文献证实,应用细胞集落刺激因子可克服肿瘤化疗和放疗引起的骨髓毒性,有利于大量强化治疗,缩短应用肿瘤化疗周期,并减少感染的并发症。
Objective: To review the progress of colony stimulating factor in order to evaluate its curative effect and safety. Methods: In recent years, domestic and foreign literature review. RESULTS AND CONCLUSION: As a representative of peptides in bioengineered drugs, the colony stimulating factor listed in the 1990s has progressed rapidly and the clinical application has also increased simultaneously. Recently, the reports of domestic and foreign professional literature are also numerous. A large number of literatures confirm that application of colony stimulating factor can overcome the bone marrow toxicity induced by chemotherapy and radiotherapy of tumor, which is beneficial to a large number of intensified treatment, shortening the cycle of application chemotherapy and reducing the complication of infection.